ALK and non-small cell lung carcinoma: ALK-rearranged NSCLC comprise 5–6% of all NSCLC and are exquisitely sensitive to ALK-directed TKIs, four of which are now approved for treatment of patients with advanced ALK-rearranged NSCLC.